2013
DOI: 10.1091/mbc.e13-05-0240
|View full text |Cite
|
Sign up to set email alerts
|

VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1

Abstract: Misfolding of cystic fibrosis transmembrane conductance regulator protein (CFTR) causes the fatal lung disease cystic fibrosis. VX-809 was developed to suppress disease-related folding defects in CFTR. VX-809 suppresses folding defects in CFTR by modulating the conformation of membrane-spanning domain 1. VX-808 is thereby able to partially restore function to F508del-CFTR and other disease-related mutants.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

40
319
1

Year Published

2014
2014
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 261 publications
(360 citation statements)
references
References 42 publications
40
319
1
Order By: Relevance
“…To further confirm the critical role of altered CFTR expression, we used VX-809 (Lumacaftor) to correct the folding and increase the amount of channels that was delivered to the cell surface 31 . We treated IB3-1 cells with 5 mM VX-809 for 48 h, and CFTR function was tested using a DiSBAC 2 (bis-(1,3-diethylthiobarbituric acid)trimethine oxonol) probe.…”
Section: Resultsmentioning
confidence: 99%
“…To further confirm the critical role of altered CFTR expression, we used VX-809 (Lumacaftor) to correct the folding and increase the amount of channels that was delivered to the cell surface 31 . We treated IB3-1 cells with 5 mM VX-809 for 48 h, and CFTR function was tested using a DiSBAC 2 (bis-(1,3-diethylthiobarbituric acid)trimethine oxonol) probe.…”
Section: Resultsmentioning
confidence: 99%
“…An interesting question in CF is whether the new class of drugs designed to facilitate folding/biogenesis of CFTR, such as Lumacaftor, influence stress in the ER 61, 62. Lumacaftor is a chaperone type drug that is designed to aid folding in the ER to enhance release of mutant CFTR to the cell surface where it has partial ion channel function.…”
Section: Oxidative and Er Stress In Chronic Inflammatory And Mucopurumentioning
confidence: 99%
“…[12][13][14][15] The most common mutation in Europe and North America, p.Phe508del, has been studied extensively and has been found to impair CFTR protein folding during synthesis. [16][17][18][19] Knowledge regarding the molecular defects caused by p.Phe508del has driven the development of targeted, interventional compounds, such as VX-809 (or Lumacaftor). Although VX-809 has shown promise in partially ameliorating the protein folding defect caused by p.Phe508del in vitro, it is yet to be determined if it will have clinical efficacy in combination with VX-770 in a phase III clinical trial.…”
mentioning
confidence: 99%